AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
55 hedge funds and large institutions have $8.42M invested in AEON Biopharma Inc in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
15% more funds holding
Funds holding: 48 → 55 (+7)
7% more capital invested
Capital invested by funds: $7.84M → $8.42M (+$576K)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
+$127K |
| 2 |
KC
Kepos Capital
New York
|
+$85.1K |
| 3 |
QGA
Q Global Advisors
Fort Worth,
Texas
|
+$73.7K |
| 4 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
+$55.3K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$47.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$62.7K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$46.8K |
| 3 |
CAC
Cowen and Company
New York
|
-$12K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.6K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
51
Centiva Capital
New York
| $5K | – | – | – |
|
|
EC
52
EJF Capital
Arlington,
Virginia
| $5K | – | – | – |
|
|
AA
53
Ancora Advisors
Cleveland,
Ohio
| $3K | – | – | – |
|
|
6CM
54
683 Capital Management
New York
| $2K | – | – | – |
|
55
UBS Group
Zurich,
Switzerland
| $1K | -$497 | -899 | -33% |
|
|
RCM
56
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| $1K | +$742 | +1,342 | New |
|
|
CAC
57
Cowen and Company
New York
| – | -$12K | -20,782 | Closed |
|
|
58
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$2K | -2,979 | Closed |
|
AEON.WS Hedge Fund Activity: Q4 2021 in Review
55 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q4 2021, worth a combined $8.42M — up 7.3% from $7.84M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AEON.WS positions and 2 closed out — a net gain of 7 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Parallax Volatility Advisers, adding an estimated $127K. The largest seller was Polar Asset Management Partners, cutting an estimated $62.7K.
- 55 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q4 2021, up from 48 in Q3 2021.
- Funds reported $8.42M of AEON Biopharma Inc stock for Q4 2021, up 7.3% quarter-over-quarter.
- 9 funds opened new AEON Biopharma Inc positions in Q4 2021 and 2 closed out, a net change of +7 holders.
- The largest AEON Biopharma Inc buyer in Q4 2021 was Parallax Volatility Advisers, an estimated $127K added.
- The largest AEON Biopharma Inc seller in Q4 2021 was Polar Asset Management Partners, an estimated $62.7K sold.
Based on aggregated 13F filings for Q4 2021.